Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected ...

On Monday, the FDA said the company could continue testing its combination COVID-19-flu and standalone flu vaccines. Novavax ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its ...

Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu ...

Novavax, Inc., based in Gaithersburg, Maryland, is a global biotechnology company focused on developing and commercializing innovative protein-based vaccines to combat serious infectious diseases, ...

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...

Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...

NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...

Novavax said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency ...

Novavax's COVID-19 vaccine continues to be its only commercial product and currently has about 2%-3% market share, according ...